We are live on ! Find out more
CMRX

Chimerix, Inc.

Delisted

CMRX was delisted on the 17th of April, 2025.

79 hedge funds and large institutions have $72.2M invested in Chimerix, Inc. in 2020 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 36 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

670% more call options, than puts

Call options by funds: $77K | Put options by funds: $10K

4% less funds holding

Funds holding: 8279 (-3)

17% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 12

18% less capital invested

Capital invested by funds: $88.1M → $72.2M (-$15.9M)

61% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 36

Holders
79
Holders Change
-3
Holders Change %
-3.66%
% of All Funds
1.59%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
14
Reduced
36
Closed
12
Calls
$77K
Puts
$10K
Net Calls
+$67K
Net Calls Change
-$13K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$9.57M -$93.1K -31,499 -0.8%
OM
2
Opaleye Management
Massachusetts
$9.56M +$5.13M +1,736,500 +82%
Renaissance Technologies
3
Renaissance Technologies
New York
$7.33M -$37K -12,500 -0.4%
Vanguard Group
4
Vanguard Group
Pennsylvania
$5.96M -$8.71K -2,946 -0.1%
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$5.77M -$33.9K -11,461 -0.5%
IC
6
Ikarian Capital
Texas
$3.4M +$4.03M +1,364,044 New
NLVP
7
New Leaf Venture Partners
New York
$3.36M
State Street
8
State Street
Massachusetts
$2.57M -$106K -35,964 -3%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$2.25M -$94K -31,795 -3%
Two Sigma Advisers
10
Two Sigma Advisers
New York
$2M +$10.9K +3,700 +0.5%
Acadian Asset Management
11
Acadian Asset Management
Massachusetts
$1.94M -$747K -252,780 -25%
Two Sigma Investments
12
Two Sigma Investments
New York
$1.6M -$228K -77,251 -11%
Northern Trust
13
Northern Trust
Illinois
$1.33M -$67.6K -22,854 -4%
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$1.22M -$149K -50,325 -9%
Jacobs Levy Equity Management
15
Jacobs Levy Equity Management
New Jersey
$1.21M -$1.01K -341 -0.1%
Man Group
16
Man Group
United Kingdom
$941K -$11.2K -3,800 -1%
Connor, Clark & Lunn Investment Management (CC&L)
17
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$886K -$194K -65,484 -16%
6CM
18
683 Capital Management
New York
$822K
Charles Schwab
19
Charles Schwab
California
$767K -$35.1K -11,878 -4%
N
20
Nuveen
North Carolina
$759K -$328K -111,010 -27%
Fidelity Investments
21
Fidelity Investments
Massachusetts
$637K -$1.65M -557,200 -69%
WVP
22
Worth Venture Partners
New Jersey
$566K -$315K -106,412 -32%
BCM
23
Bridgeway Capital Management
Texas
$505K -$12.7K -4,300 -2%
DC
24
Diametric Capital
Massachusetts
$500K -$209K -70,806 -26%
AQR Capital Management
25
AQR Capital Management
Connecticut
$479K +$569K +192,458 New

CMRX Hedge Fund Activity: Q3 2020 in Review

79 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Chimerix, Inc. (CMRX) for Q3 2020, worth a combined $72.2M — down 18% from $88.1M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of CMRX and 10 opened new positions — a net loss of 2 holders — while 36 trimmed existing stakes and 14 added.

The largest buyer was Opaleye Management, adding an estimated $5.13M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.94M sold.

  • 79 institutional investors held Chimerix, Inc. (CMRX) as of Q3 2020, down from 82 in Q2 2020.
  • Funds reported $72.2M of Chimerix, Inc. stock for Q3 2020, down 18% quarter-over-quarter.
  • 10 funds opened new Chimerix, Inc. positions in Q3 2020 and 12 closed out, a net change of -2 holders.
  • The largest Chimerix, Inc. buyer in Q3 2020 was Opaleye Management, an estimated $5.13M added.
  • The largest Chimerix, Inc. seller in Q3 2020 was Point72 Asset Management, an estimated $1.94M sold.

Based on aggregated 13F filings for Q3 2020.